Preetam Shah serves as Executive at BRAINSTORM CELL THERAPEUTICS INC., where they oversee executive responsibilities. Since joining the company, Preetam Shah has executed 13 insider transactions totaling $111.6K, demonstrating a bullish approach to their equity position. Their most recent transaction on Mar 15, 2024 involved receiving (via award) 108,750 shares valued at $0.
Preetam Shah currently holds 335,960 shares of BRAINSTORM CELL THERAPEUTICS INC. (BCLI), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Preetam Shah has been a net buyer of BCLI stock. They have purchased $76.7K and sold $34.9K worth of shares.
Preetam Shah's most recent insider trade was on Mar 15, 2024, when they sold 108,750 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $0.67 |
| Discretionary |
| Mar 27, 2023 | CDTX | $0 | Award | 90,000 | $N/A | Discretionary |
| Mar 13, 2023 | CDTX | $10.2K | Sale | 6,648 | $1.53 | Discretionary |
| Sep 19, 2022 | CDTX | $12.0K | Sale | 15,642 | $0.77 | Discretionary |
| Sep 15, 2022 | CDTX | $0 | Option Exercise | 50,000 | $N/A | Discretionary |
| Mar 31, 2022 | CDTX | $0 | Award | 51,250 | $N/A | Discretionary |
| Mar 31, 2022 | CDTX | $20.6K | Payment | 24,820 | $0.83 | Discretionary |
| Mar 31, 2022 | CDTX | $0 | Award | 66,001 | $N/A | Discretionary |
| Nov 12, 2021 | CDTX | $30.8K | Purchase | 20,000 | $1.54 | Discretionary |
| Dec 30, 2020 | BCLI | $116.0K | Payment | 25,000 | $4.64 | Discretionary |
| Dec 24, 2019 | BCLI | $45.9K | Purchase | 11,600 | $3.96 | Discretionary |
| Sep 6, 2019 | BCLI | $0 | Award | 25,000 | $N/A | Discretionary |